Skip to main content
Top
Published in: PharmacoEconomics 1/2000

01-07-2000 | Leading Article

Introduction to the Pharmacoeconomics of Herbal Medicines

Authors: Dr Peter A. G. M. De Smet, Gouke Bonsel, Ary Van der Kuy, Yechiel A. Hekster, Marja H. Pronk, Mark J. A. Brorens, Jacques H. M. Lockefeer, Mark J. C. Nuijten

Published in: PharmacoEconomics | Issue 1/2000

Login to get access

Abstract

This article explores the need to perform pharmacoeconomic evaluations of herbal medicines and assesses the extent to which this approach has been applied so far to these products. There seems to be no compelling need for pharmacoeconomic analyses of herbal over-the-counter medicines, but such analyses are certainly warranted for herbal prescription medicines that have a high level of reimbursement. Such preparations are used in Germany, in particular, where physicians prescribed ginkgo, hawthorn, St John’s wort, horse-chestnut and saw palmetto to a value of more than DM50 million each in 1996.
In our survey, only a single pharmacoeconomic study, of uncertain quality, was found on these 5 herbs, whereas several pharmacoeconomic reports on synthetic competitors were retrieved. The time has come to submit highly reimbursed herbal prescription medicines to the same rigorous pharmacoeconomic evaluations as their synthetic competitors. At present, such studies are particularly important for Germany, but in the future they may also become relevant for other countries, inside as well as outside Europe.
Footnotes
1
According to a follow-up survey on the use of alternative medicine in the US in 1997, the percentage of respondents who had used a herbal medicine in the past 12 months had increased to asmuch as 12%, and 15%of these users had seen an alternative medicine practitioner.[8]
 
Literature
1.
go back to reference Sheehan MP, Rustin MH, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992; 340: 13–7PubMedCrossRef Sheehan MP, Rustin MH, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992; 340: 13–7PubMedCrossRef
2.
go back to reference De Smet PAGM. The role of plant-derived drugs and herbal medicines in health care. Drugs 1997; 54: 801–40PubMedCrossRef De Smet PAGM. The role of plant-derived drugs and herbal medicines in health care. Drugs 1997; 54: 801–40PubMedCrossRef
3.
go back to reference De Smet PAGM, Brouwers JRBJ. Pharmacokinetic evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 1997; 32 (6): 1–10 De Smet PAGM, Brouwers JRBJ. Pharmacokinetic evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 1997; 32 (6): 1–10
5.
go back to reference De Smet PAGM. Adverse effects of herbal remedies. Adv Drug React Bull 1997; 183: 695–8CrossRef De Smet PAGM. Adverse effects of herbal remedies. Adv Drug React Bull 1997; 183: 695–8CrossRef
6.
go back to reference De Smet PAGM, Stricker BH, Nijman JJ. Indirecte risico’s van alternatieve middelen: een oproep tot het rapporteren van concrete gevallen. Med Contact 1994; 49: 1593–4 De Smet PAGM, Stricker BH, Nijman JJ. Indirecte risico’s van alternatieve middelen: een oproep tot het rapporteren van concrete gevallen. Med Contact 1994; 49: 1593–4
7.
go back to reference Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246–52PubMedCrossRef Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246–52PubMedCrossRef
8.
go back to reference Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569–75PubMedCrossRef Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569–75PubMedCrossRef
9.
go back to reference MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996; 347: 569–73PubMedCrossRef MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996; 347: 569–73PubMedCrossRef
10.
go back to reference World herbal medicine market estimates. Scrip 1993 May 21; 1822: 22 World herbal medicine market estimates. Scrip 1993 May 21; 1822: 22
11.
go back to reference Who’s doing what in herbal medicines. Marketletter 1992 Aug 24: 24–5 Who’s doing what in herbal medicines. Marketletter 1992 Aug 24: 24–5
13.
go back to reference Germany leads in branded phytomedicines. OTC Bulletin 1996 Jun 14: 15 Germany leads in branded phytomedicines. OTC Bulletin 1996 Jun 14: 15
14.
go back to reference Carlsten A, Wennberg M, Bergendal L. The influence of Rx-to-OTC changes on drug sales: experiences from Sweden 1980- 1994. J Clin Pharm Ther 1996; 21: 423–30PubMedCrossRef Carlsten A, Wennberg M, Bergendal L. The influence of Rx-to-OTC changes on drug sales: experiences from Sweden 1980- 1994. J Clin Pharm Ther 1996; 21: 423–30PubMedCrossRef
15.
go back to reference Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med 1995; 123: 493–9PubMed Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med 1995; 123: 493–9PubMed
16.
go back to reference Schwabe U, red. Arzneiverordnungs-Report ’97. Aktuelle Daten, Kosten, Trends und Kommentare. Stuttgart: Gustav Fischer Verlag, 1997 Schwabe U, red. Arzneiverordnungs-Report ’97. Aktuelle Daten, Kosten, Trends und Kommentare. Stuttgart: Gustav Fischer Verlag, 1997
17.
go back to reference Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer’s disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191–200PubMed Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer’s disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191–200PubMed
18.
go back to reference Henke CJ, Burchmore MJ. The economic impact of the tacrine in the treatment of Alzheimer’s disease. Clin Ther 1997; 19: 330–45PubMedCrossRef Henke CJ, Burchmore MJ. The economic impact of the tacrine in the treatment of Alzheimer’s disease. Clin Ther 1997; 19: 330–45PubMedCrossRef
19.
go back to reference Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol 1995; 25 Suppl. 2: S44–50 Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol 1995; 25 Suppl. 2: S44–50
20.
go back to reference Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914–9PubMedCrossRef Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914–9PubMedCrossRef
21.
go back to reference McMurray JJ, McGuire A, Davie AP, et al. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411–5PubMedCrossRef McMurray JJ, McGuire A, Davie AP, et al. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411–5PubMedCrossRef
22.
go back to reference Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 1997; 10: 272–95CrossRef Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 1997; 10: 272–95CrossRef
23.
go back to reference Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715–30PubMed Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715–30PubMed
24.
go back to reference Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897–902PubMedCrossRef Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897–902PubMedCrossRef
25.
go back to reference Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47–58PubMedCrossRef Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47–58PubMedCrossRef
26.
go back to reference Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995; 46: 477–83PubMedCrossRef Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995; 46: 477–83PubMedCrossRef
27.
go back to reference Ilker Y, Tarcan T, Akdas A. Economics of different treatment options of benign prostatic hyperplasia in Turkey. Int Urol Nephrol 1996; 28: 525–8PubMedCrossRef Ilker Y, Tarcan T, Akdas A. Economics of different treatment options of benign prostatic hyperplasia in Turkey. Int Urol Nephrol 1996; 28: 525–8PubMedCrossRef
28.
go back to reference Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169–78PubMedCrossRef Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169–78PubMedCrossRef
29.
go back to reference Rychlik R, Marshall M, Bachinger A, et al. Ökonomische Aspekte der Therapie der chronisch venösen Insuffizienz. Gesundh ökon. Qual Manag 1997; 2: 86–91 Rychlik R, Marshall M, Bachinger A, et al. Ökonomische Aspekte der Therapie der chronisch venösen Insuffizienz. Gesundh ökon. Qual Manag 1997; 2: 86–91
30.
go back to reference Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347: 292–4PubMedCrossRef Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347: 292–4PubMedCrossRef
31.
go back to reference Switzerland reimburses St John’s wort. Scrip 1998 Jan 23; 2303: 4 Switzerland reimburses St John’s wort. Scrip 1998 Jan 23; 2303: 4
32.
go back to reference World self-medication sales up 2%. Scrip 1998 Apr 10; 2325: 16 World self-medication sales up 2%. Scrip 1998 Apr 10; 2325: 16
Metadata
Title
Introduction to the Pharmacoeconomics of Herbal Medicines
Authors
Dr Peter A. G. M. De Smet
Gouke Bonsel
Ary Van der Kuy
Yechiel A. Hekster
Marja H. Pronk
Mark J. A. Brorens
Jacques H. M. Lockefeer
Mark J. C. Nuijten
Publication date
01-07-2000
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 1/2000
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200018010-00001

Other articles of this Issue 1/2000

PharmacoEconomics 1/2000 Go to the issue

Review Article

Social Phobia